CSPC Pharmaceutical (HKG:1093) granted an exclusive license to Cipla USA to sell its irinotecan liposome injection in the US, according to a Thursday filing with the Hong Kong bourse.

The injection is indicated for the treatment of multiple solid tumors such as metastatic pancreatic cancer, colorectal cancer, lung cancer, and cervical cancer, the filing said.

Under the agreement, CSPC Pharma will get an upfront payment of $15 million and may be eligible to obtain up to $25 million in potential first commercial sale and regulatory milestone payments.

CSPC could also receive up to $1.03 billion in additional commercial sales milestone payments, the filing said.